Pravastatin for prevention of HELLP syndrome: A case report

RATIONALE: Pravastatin has emerged for prevention and treatment of preeclampsia; no reports are available on pravastatin and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome. PATIENT CONCERNS: The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5...

Descripción completa

Detalles Bibliográficos
Autores principales: Otten, Lucia Anna, van der Ven, Katrin, Kühr, Marietta, Gembruch, Ulrich, Merz, Waltraut Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
5600
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5662375/
https://www.ncbi.nlm.nih.gov/pubmed/29049209
http://dx.doi.org/10.1097/MD.0000000000008229
Descripción
Sumario:RATIONALE: Pravastatin has emerged for prevention and treatment of preeclampsia; no reports are available on pravastatin and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome. PATIENT CONCERNS: The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5 for HELLP. Intrauterine fetal death at GA 22+5 occurred in the second pregnancy, whilst on temporizing management of HELLP. DIAGNOSES: Severe, recurrent early-onset HELLP syndrome. INTERVENTIONS: In her fourth pregnancy, pravastatin was commenced at GA 13. OUTCOMES: The course of pregnancy was uncomplicated, and a healthy, appropriate for gestational age fetus was delivered at term. LESSONS: Pravastatin may be effective in prevention of HELLP. The hepatic uptake may be of particular advantage.

Ejemplares similares